| 000 | 03206cam a2200457 4500500 | ||
|---|---|---|---|
| 005 | 20250121155347.0 | ||
| 041 | _afre | ||
| 042 | _adc | ||
| 100 | 1 | 0 |
_aMelé-Ninot, Gemma _eauthor |
| 700 | 1 | 0 |
_a Serra-Baldrich, Esther _eauthor |
| 700 | 1 | 0 |
_a Spertino, Jorge _eauthor |
| 700 | 1 | 0 |
_a Guilarte, Mar _eauthor |
| 700 | 1 | 0 |
_a Ribó González, Paula _eauthor |
| 700 | 1 | 0 |
_a Lleonart-Bellfill, Ramon _eauthor |
| 700 | 1 | 0 |
_a Figueras-Nart, Ignasi _eauthor |
| 700 | 1 | 0 |
_a Bonfill-Ortí, Montserrat _eauthor |
| 700 | 1 | 0 |
_a Depreux, Nathalie _eauthor |
| 700 | 1 | 0 |
_a Sala-Cunill, Anna _eauthor |
| 700 | 1 | 0 |
_a Bielsa-Marsol, Isabel _eauthor |
| 700 | 1 | 0 |
_a Baliu-Piqué, Carola _eauthor |
| 700 | 1 | 0 |
_a Sanmartín-Novell, Verònica _eauthor |
| 700 | 1 | 0 |
_a Garcia-Navarro, Xavier _eauthor |
| 700 | 1 | 0 |
_a Expósito-Serrano, Vicente _eauthor |
| 700 | 1 | 0 |
_a Garnica-Velandia, Diana _eauthor |
| 700 | 1 | 0 |
_a Diaz-Sarrió, Maria Carmen _eauthor |
| 700 | 1 | 0 |
_a Gómez-Armayones, Sara _eauthor |
| 700 | 1 | 0 |
_a Gich Saladich, Ignasi _eauthor |
| 700 | 1 | 0 |
_a Giménez-Arnau, Ana _eauthor |
| 245 | 0 | 0 | _aAre antihistamines still used during omalizumab treatment for chronic spontaneous urticaria? |
| 260 | _c2022. | ||
| 500 | _a32 | ||
| 520 | _aBackgroundThe guidelines for the treatment of chronic spontaneous urticaria (CSU) recommend adding omalizumab to the treatment of patients with uncontrolled disease despite four-fold doses of second-generation antihistamines (AH). On the contrary, some studies revealed that omalizumab was effective without concomitant AH and several authors suggest tapering off AH when CSU is controlled with omalizumab.ObjectivesThe aim of our study was to evaluate the use of AH during treatment with omalizumab in patients with CSU in real clinical practice.Materials & MethodsThis was a multicentre cross-sectional and observational study conducted by the Catalan and Balearic Chronic Urticaria Network (XUrCB) based on a cohort of 298 CSU patients treated with omalizumab.ResultsIn total, 23.5% of our patients decided themselves to stop taking AH during omalizumab treatment. The ratio of patients with CSU without concomitant inducible urticaria and the percentage of patients with a good response to omalizumab (UAS7≤6 and/or UCT ≥12) were higher in those who stopped taking AH.ConclusionMore studies are required to identify the phenotypic characteristics of patients responding to omalizumab as monotherapy in order to avoid overtreating with AH. Our study suggests that patients with CSU without concomitant inducible urticaria and those who achieve a good response to omalizumab tend to be controlled by omalizumab without AH. In order to establish guidelines on how to stop AH, further evidenced-based studies are required. | ||
| 690 | _aantihistamines | ||
| 690 | _achronic urticaria | ||
| 690 | _achronic spontaneous urticaria | ||
| 690 | _aantihistamines | ||
| 690 | _achronic urticaria | ||
| 690 | _achronic spontaneous urticaria | ||
| 786 | 0 | _nEuropean Journal of Dermatology | 32 | 5 | 2022-09-01 | p. 629-631 | 1167-1122 | |
| 856 | 4 | 1 | _uhttps://shs.cairn.info/revue-european-journal-of-dermatology-2022-5-page-629?lang=en&redirect-ssocas=7080 |
| 999 |
_c604545 _d604545 |
||